AzTrials
AzTrials

Bicuspid Aortic Valve DiseaseBAVConNCT01980797

International Bicuspid Aortic Valve Consortium (BAVCon)

An observational study of Bicuspid Aortic Valve Disease and Thoracic Aortic Disease in Patients With a Bicuspid Aortic Valve, run by Boston University at 12 sites in 5 countries.

Active, not recruiting

Under way, not looking for participants. Everyone needed has enrolled. The study is still running.

Official record
Search all trials

Trial summary

Bicuspid aortic valve (BAV) disease is the most frequent congenital cardiac malformation, occurring in 0.5-1.2% of the US population. In young adults, it is generally a benign abnormality; but in older adults it is associated with thoracic aortic aneurysm or dissection in 20-30% of those with BAV. Read more about this study

Who is it for?
Ages 8 to 90 years
How many people
6,464 participants
Where
12 sitesin 5 countries
Study dates
Nov 2013to Nov 2028
How long will I take part?
20 Years
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 8 to 90 years
  • All sexes
  • No healthy volunteers
  • Child, Adult, Older adult

Study population: Patients with and without bicuspid aortic valves disease

Who may be able to join

  • Patients diagnosed as having a bicuspid aortic valve
  • All ages ≥8 years
  • Able to provide fully informed consent

Who cannot join

  • None

Trial locations and contacts

12 sites in 5 countries.

12 sites in 5 countries

United States5 sites
  • University of Michigan

    Ann Arbor, Michigan, 48109

  • Tufts Medical Center

    Boston, Massachusetts, 02111

  • Boston Medical Center

    Boston, Massachusetts, 02218

  • University of Texas Health Science Center at Houston

    Houston, Texas, 77030

  • Mayo Clinic

    Rochester, Minnesota, 55905

Other trials in United States

Italy4 sites
  • Monaldi Hospital

    Naples, 80100

  • Second University of Naples

    Naples, 80131

  • University of Salerno

    Salerno, 36-83023

  • Istituto Policlinico San Donato

    San Donato Milanese, Milan, 20097

Other trials in Italy

Canada1 site
  • Laval University

    Québec, Quebec, G1V 4G5

Other trials in Canada

Spain1 site
  • Hospital Vall d'Hebron

    Barcelona, 08035

Other trials in Spain

United Kingdom1 site
  • University of Oxford

    Oxford, OX3 9DU

Other trials in United Kingdom

About this study

Bicuspid aortic valve (BAV) disease is the most frequent congenital cardiac malformation, occurring in 0.5-1.2% of the US population. In young adults, it is generally a benign abnormality; but in older adults it is associated with thoracic aortic aneurysm or dissection in 20-30% of those with BAV. BAV is strongly associated with early development of aortic valve calcification or incompetence in >50% of BAV patients, and accounts for ~40% of the >30,000 aortic valve replacements (AVR) performed in the US each year. Yet, we know little of the etiology, cellular events and modifiers of progression of BAV to calcific aortic valve disease and we still do not understand the genetic cause(s) of BAV despite evidence for its high heritability.

The Specific Aims of this study are:

Read more
  1. To identify the genetic causes of bicuspid aortic valve disease and its associated thoracic aortic disease.
  2. To identify potential pathways to predict the clinical course of BAV disease and for treating human BAV disease.

To achieve these aims, we have created the International Bicuspid Aortic Valve Consortium (BAVCon), a consortium of institutions with cohorts of BAV patients and the expertise to fulfill the performance of these aims.

Read the detailed description

The International Bicuspid Aortic Valve Consortium (BAVCon) Registry is the data collection arm of the International Bicuspid Aortic Valve Consortium, a 16 institution international consortium of investigators with interests in the genetics, molecular biology, imaging, surgery and natural history of bicuspid aortic valve disease.

The BAVCon Registry is a longitudinal cohort study, which is observational by design. The cohort will consist of patients with BAV. Consideration will be given to eventual inclusion of a disease-free control or comparison group. The study will compare genetic risk factors, cross-sectional and longitudinal data on risk factors related to the diagnosis, treatment and outcomes among groups of enrolled patients. As part of the natural course of clinical care, the patients and their physicians will determine the approach to treatment and the study will record the observed related outcomes. The study will not attempt to interfere with the outcomes through any type of planned intervention; therefore, there are no anticipated adverse events as a result of study participation.

Study Design

The Registry is designed to capture information on patients with bicuspid aortic valve disease. The BAVCon Registry population will be comprised of patients from sixteen BAVCon Clinical Centers. The participating BAVCon Clinical Centers are:

  • Boston University School of Medicine, Boston (Dr. Simon Body, Consortium PI)
  • GenTAC Consortium (Dr. Kim Eagle, PI)
  • Hospital Vall d'Hebron, Barcelona, Spain (Dr. Arturo Evangelista, PI)
  • Monaldi Hospital, Naples, Italy (Dr. Giuseppe Limongelli, PI)
  • Mayo Clinic, Rochester (Dr. Hector Michelena, PI)
  • Oxford University, Oxford, England (Dr. Malenka Bissell, PI)
  • San Donato Hospital IRCCS, Milan, Italy (PI: Dr. Alessandro Frigiola)
  • Tufts University, Boston (Dr. Gordon Huggins, PI)
  • Université Laval, Quebec (Dr. Yohan Bossé, PI)
  • University of Michigan, Ann Arbor (Dr. Bo Yang, PI)
  • University of Salerno, Salerno, Italy (Dr. Eduardo Bossone, PI)
  • University of Texas Medical School, Houston (Dr. Dianna Milewicz, PI) One center with specific expertise, but not enrolling patients, is University of Ottawa (Dr. Mona Nemer, PI).

The data supplied by each participating center are collected from the following sources:

Patient interview or questionnaire Hospital medical records Surgical records Imaging studies

Enrollment Information about the Registry will be disseminated to potential study subjects using a number of sources. The principal means of enrollment will be from the Cardiology and Surgical Clinics of each Hospital. In addition, collaborations with the patient advocacy groups such as the Bicuspid Aortic Valve Foundation. These organizations have well established resources for providing information to patients such as websites, newsletters, and national conferences. A recruitment brochure has been developed to explain the goals and basic procedures of the Registry. Finally, the study website, http://www.bavcon.org, will inform potential subjects about the Registry. All recruitment materials will be approved by the DCC and BCC IRBs, as appropriate, prior to dissemination.

BCC study staff will identify eligible patients using the eligibility criteria developed and approved by the Steering Committee. They will both screen their current patient population as well as identify new patients that attend the clinic. Eligible patients will be solicited during clinic visits according to protocols approved by the local IRB.

Initially, a care provider will introduce the Registry to the patient or the parent or guardian of the patient, and ask if they are interested in talking further with the research coordinator. If the patient (or parent or guardian) agrees, the research coordinator will meet with the patient for a more comprehensive explanation of the Registry. If there is continued agreement, the research coordinator will proceed with the consent and enrollment process. Signed informed consent will be obtained prior to any data or sample collection. Patients will receive a hard-copy of the consent form to keep. Patients will be able to ask questions at any time. One parent or guardian may provide signed consent for a minor child or other person with a physical or mental condition that prevents them from doing so themselves. Literacy in the native language of the country (English and Spanish in the USA) will be required of the consenting patient or parent/guardian. Child assent will be obtained from children at least 8 years of age, or as determined by the local IRB. Across all the sites, we anticipate total enrollment of up to 10,000 patients.

Eligibility Criteria

Inclusion criteria for entry into the Registry are:

  • Patients diagnosed with bicuspid aortic valve
  • All ages ≥8 years
  • Able to provide fully informed consent

Local Site Restrictions Some sites will not be collecting tissue from patients, therefore information on tissue collection will be absent. Some sites do not routinely perform CT or MRI on their patients, so these data will also be absent.

Keywords
Bicuspid aortic valve disease, Thoracic aortic disease, Genetics, Echocardiography, Cardiac CT, Cardiac MRI
Medical subject headings
Bicuspid Aortic Valve Disease

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Study groups in NCT01980797
Study groupRoleWhat they receive
Bicuspid aortic valve diseaseGroup/Cohort Label - Bicuspid aortic valve Group/Cohort Description - * Patients diagnosed with bicuspid aortic valve * All ages ≥8 years * Able to provide fully informed consent
Tricuspid aortic valve control patientsGroup/Cohort Label - Tricuspid aortic valve control patients Group/Cohort Description -Control patients will come from approximately matched patients without an identified bicuspid aortic valve who are trace, gender and geographically matched. * Patients not diagnosed with bicuspid aortic valve * All ages ≥8 years * Able to provide fully informed consent

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Bicuspid aortic valve disease

    The first specific aim is to identify the genetic causes of bicuspid aortic valve disease.

    Measured: 10 years

Secondary outcomes (1)
  1. The development of thoracic aortic disease in patients with bicuspid aortic valve disease

    The second specific aim is to identify genetic and non-genetic factors to cause thoracic aortic disease in BAV patients.

    Measured: 10 years

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted11 Nov 2013 (estimated)
  2. Study startNov 2013
  3. Primary completionNov 2028 (estimated)
  4. Study completionNov 2028 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
6,464 participants (actual)
Target duration
20 Years
IDs, dates and publications
ClinicalTrials.gov ID
NCT01980797
Sponsor's protocol ID
H-39760
Other IDs
1R21HL150373-01
Acronym
BAVCon
Status last verified
Mar 2026
First submitted
5 Nov 2013
Last updated
1 Apr 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

An observational study of Bicuspid Aortic Valve Disease and Thoracic Aortic Disease in Patients With a Bicuspid Aortic Valve, run by Boston University at 12 sites in 5 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: under way, not looking for participants, as of the sponsor's last update on 1 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 12 sites in United States, Italy, Canada, Spain, United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Bicuspid aortic valve disease (time frame: 10 years). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 Apr 2026; AzTrials last refreshed its copy on 30 Oct 2026.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in